Nuciferine
![]() | |
Names | |
---|---|
IUPAC name
1,2-Dimethoxy-6aβ-aporphine
| |
Systematic IUPAC name
(6aR)-1,2-Dimethoxy-6-methyl-5,6,6a,7-tetrahydro-4H-dibenzo[de,g]quinoline | |
Other names
(R)-1,2-Dimethoxyaporphine
| |
Identifiers | |
3D model (
JSmol ) |
|
ChEMBL | |
ChemSpider | |
PubChem CID
|
|
UNII | |
CompTox Dashboard (EPA)
|
|
| |
SMILES
| |
Properties | |
C19H21NO2 | |
Molar mass | 295.376 g/mol |
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
|
Nuciferine is an
Preliminary psychopharmacological research in 1978 was unable to conclusively determine the compound's classification regarding dopamine-receptor activity.[3] On one hand, investigative studies found evidence of behavior traditionally associated with dopamine-receptor stimulation: stereotypy, increase in spontaneous motor activity, inhibition of conditioned avoidance response, and an increase in pain sensitivity resulting in an inhibition of morphine analgesia.[3] On the other hand, these early investigative studies also found evidence of behavior traditionally associated with dopamine-receptor blockade: decrease of spontaneous motor activity, chills, catalepsy, trance-like states of consciousness.[3]
Nuciferine exhibits a receptor profile similar to atypical
Pharmacology
Nuciferine has been reported to have various anti-inflammatory effects, possibly mediated via PPAR delta activation.[5]
According to a newer study from 2016, Nuciferine acts as an
In rodent models relating to antipsychotic drug effects, Nuciferine has shown various actions such as blocking head-twitch responses and discriminative stimulus effects of a 5-HT2A agonist, enhancing amphetamine-induced locomotor activity, inhibiting phencyclidine (PCP)-induced locomotor activity, and restoring PCP-induced disruption of pre-pulse inhibition without inducing catalepsy.[4]
Nuciferine may also potentiate